J Cancer 2020; 11(15):4332-4342. doi:10.7150/jca.44545

Review

Blood-based Markers in the Prognostic Prediction of Esophagogastric Junction Cancer

Can-Tong Liu1,2, Chao-Qun Hong3, Xu-Chun Huang1,2, En-Min Li4, Yi-Wei Xu1,2,✉, Yu-Hui Peng1,2,✉

1. Department of Clinical Laboratory Medicine, the Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China
2. Precision Medicine Research Center, Shantou University Medical College, Shantou, Guangdong, China
3. Department of Oncological Laboratory Research, the Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China
4. Department of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou, Guangdong, China

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Liu CT, Hong CQ, Huang XC, Li EM, Xu YW, Peng YH. Blood-based Markers in the Prognostic Prediction of Esophagogastric Junction Cancer. J Cancer 2020; 11(15):4332-4342. doi:10.7150/jca.44545. Available from http://www.jcancer.org/v11p4332.htm

File import instruction

Abstract

Esophagogastric junction cancer poses a great threat to human beings both in western countries and East Asia, especially in China and Japan, and its incidence has increased during recent decades. The 5-year survival rate of esophagogastric junction cancer is quite poor compared with that of other gastric cancer sites. Until now, the traditional TNM staging system has been widely used in clinical practice for prognosis. However, the TNM system is based on pathology after surgical resection or radiology using CT and MRI, not on blood markers. Evidently, some research has been reported concentrated on the prognostic value of blood-based markers with the character of non-invasive and non-radioactive in EJA. Hematologic, biochemical and coagulation parameters could be obtained from clinical data and utilized to analyze their prognostic values. Tumor-associated antigens, microRNAs and circulating tumor cells have also been reported in EJC prognosis. In this article, we review research focused on blood-based markers to evaluate their prognostic value in esophagogastric junction cancer, especially its main subtype adenocarcinoma.

Keywords: esophagogastric junction cancer, blood-based marker, prognosis